TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Evidence linking cholesterol-lowering drugs to Alzheimer’s prevention or treatment remains inconclusive. A Danish observational study associated statin use with lower dementia risk in people with Type 2 diabetes, while an experimental drug reduced a blood Alzheimer’s biomarker in a subgroup of a heart-disease trial; neither result proves that cholesterol drugs prevent or treat Alzheimer’s.
New research has renewed questions about whether cholesterol-lowering drugs could affect Alzheimer’s, but there is not yet evidence that they prevent or treat the disease. A Danish records study linked statin use with lower dementia risk in people with Type 2 diabetes, while a separate trial of the experimental drug obicetrapib found lower levels of an Alzheimer’s-related blood biomarker in a subgroup carrying the ApoE4 risk gene.
The Danish study, published in The Lancet Regional Health – Europe, examined electronic health records for more than 130,000 people with Type 2 diabetes. Researchers reported that participants who began statins earlier had a 15% lower risk of dementia over a decade, while those who started later had a 10% lower risk. The study was observational: it found an association and cannot establish that statins caused the difference.
In a separate Phase 3 trial involving people with heart disease or a genetic form of high cholesterol, NewAmsterdam Pharma studied obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor. Among 1,727 participants with the ApoE4 gene, the company reported lower blood levels of pTau-217, a biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. A biomarker change is not the same as showing improved memory, delayed symptoms or reduced disease risk.
NewAmsterdam has enrolled the first participant in a Phase 2b Alzheimer’s trial of obicetrapib. The study is designed to test whether a year of treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. Its reported focus is biomarkers, not proof of clinical benefit.
Why Cholesterol Findings Matter
Dementia affects individuals, families and health systems, so even a modest reduction in risk could matter if it were confirmed across a large population. Statins are already prescribed to reduce cardiovascular risks, including stroke, for many people with Type 2 diabetes. The Danish results may support further investigation of whether treatment timing is relevant, but they do not establish a reason to take statins specifically to prevent Alzheimer’s.
The obicetrapib finding points to a different research question: whether a drug that changes cholesterol handling might also affect processes reflected in Alzheimer’s biomarkers. If the Phase 2b study finds a biomarker effect, that could inform later research. It would still not show that the drug prevents dementia or improves cognition. Clinical outcomes remain the key unanswered issue.
As an affiliate, we earn on qualifying purchases.
Why Statin Evidence Is Mixed
Earlier randomized trials of statins did not show that the drugs treated cognitive decline, according to the report. A later randomized trial in healthy adults over 70 also did not find a dementia-prevention effect. These findings differ from observational research, which can identify patterns but is vulnerable to differences between people who take a medication and those who do not.
Mayo Clinic neurologist David Knopman told Being Patient that statin users may be more medically informed and more likely to follow other healthy behaviours than nonusers, making the groups difficult to compare. Long-term prevention trials may also be difficult to fund: statins are off-patent, and Knopman said a lengthy study may not be financially attractive to drug companies.
Cholesterol in the blood does not simply pass into the brain, according to the report. Researchers are studying whether changes in cholesterol metabolism within the brain may contribute to Alzheimer’s. University of Virginia endocrinologist Heather Ferris said conventional statins may not be the right approach because they do not readily reach the brain to alter its cholesterol metabolism.
““It’s unknown.””
— David Knopman, Mayo Clinic neurologist, speaking to Being Patient
Alzheimer's blood biomarker test kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Biomarkers Are Not Clinical Benefit
The Danish study cannot determine whether statins lowered dementia risk or whether other differences between patients explain the association. The source also describes a randomized trial in healthy older adults that found no dementia-prevention effect, underscoring that the evidence is mixed.
For obicetrapib, the reported pTau-217 result came from a subgroup of a trial designed around heart disease or genetic high cholesterol. It does not establish that the drug changes Alzheimer’s progression. The available report does not provide the size of the biomarker reduction or show results for cognition, daily function or dementia incidence. Whether the drug’s effect reflects changes in the brain, and whether any such change benefits patients, remains uncertain.
Neither finding supports starting, stopping or changing cholesterol medication for Alzheimer’s without a clinician’s guidance. The drugs have established cardiovascular uses, but their role in Alzheimer’s is still under investigation.
As an affiliate, we earn on qualifying purchases.
Results From the Alzheimer’s Trial
The next reported milestone is the Phase 2b obicetrapib study, which will examine whether a year of treatment changes Alzheimer’s biomarkers in people with disease hallmarks but no symptoms. Researchers and readers will need results from that trial to judge whether the earlier blood-marker finding is reproduced in a group selected for Alzheimer’s-related features.
Even a positive biomarker result would be an intermediate research finding. Further studies would be needed to test whether treatment affects cognitive decline or the development of dementia. The timing of the Phase 2b results was not stated in the source material.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does the Danish study prove statins prevent dementia?
No. It found an association between statin use and lower dementia risk among people with Type 2 diabetes, but an observational study cannot show that statins caused the difference.
Did obicetrapib improve memory or treat Alzheimer’s?
The reported finding was a reduction in blood pTau-217 among a subgroup carrying the ApoE4 gene. The report does not say that the drug improved memory, treated symptoms or slowed Alzheimer’s.
What will the Phase 2b trial test?
It will examine whether a year of obicetrapib treatment changes Alzheimer’s biomarkers in people with disease hallmarks but no symptoms. The source does not report that the trial is designed to prove prevention or clinical benefit.
Should people take statins to prevent Alzheimer’s?
The evidence described here does not establish statins as Alzheimer’s prevention or treatment. People should discuss cholesterol medication and any changes to it with a qualified health professional, based on their individual medical needs.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
